Ines Bruno

Prof. Ines Bruno

Department of Pharmacy, University of Salerno, 84084 Fisciano, SA, Italy

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2014 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
GLGianluigi Lauro
Gianluigi Lauro
MSMaria Strocchia
Maria Strocchia
STStefania Terracciano
Stefania Terracciano
Ines BrunoInes Bruno
Ines Bruno
KFKatrin Fischer
Katrin Fischer
GBGiuseppe Bifulco
Giuseppe Bifulco

5 March 2015 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
SPSarah Picaud
Sarah Picaud
MSMaria Strocchia
Maria Strocchia
STStefania Terracciano
Stefania Terracciano
GLGianluigi Lauro
Gianluigi Lauro
JMJacqui Mendez
Jacqui Mendez
PFPanagis Filippakopoulos
Panagis Filippakopoulos
The 2-amine-9H-purine scaffold was identified as a weak bromodomain template and was developed via iterative structure based design into a potent nanomolar ligand for the bromodomain of human BRD9 with small residual micromolar affinity toward the bromodomain of BRD4. Binding of the lead compound 11 to the bromodomain of BRD9 results in an unprecedented rearrangement of residues forming the acetyllysine recognition site, affecting plasticity of the protein in an induced-fit pocket. The compound does not exhibit any cytotoxic effect in HEK293 cells and displaces the BRD9 bromodomain from chromatin in bioluminescence proximity assays without affecting the BRD4/histone complex. The 2-amine-9H-purine scaffold represents a novel template that can be further modified to yield highly potent and selective tool compounds to interrogate the biological role of BRD9 in diverse cellular systems.

1 April 2006 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
Manuela RodriquezManuela Rodriquez
Manuela Rodriquez
MAMaurizio Aquino
Maurizio Aquino
Ines BrunoInes Bruno
Ines Bruno
GMGiovanni Martino
Giovanni Martino
MTMaurizio Taddei
Maurizio Taddei
LGLuigi Gomez-Paloma
Luigi Gomez-Paloma
Chromatin remodeling is a fundamental phenomenon in the life of eukaryotic cells, bearing implications to numerous physiological and pathological phenomena. This review outlines the chemistry of natural and synthetic agents endowed with the ability to interfere with such biological function, with a particular emphasis on histone deacetylase (HDAC) inhibitors. Other aspects covered in this article comprise structure activity relationships (SAR) and modes of action at molecular level, including the description of crystal structures of enzyme-inhibitor complexes.

9 January 2015 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Closed access
STStefania Terracciano
Stefania Terracciano
GLGianluigi Lauro
Gianluigi Lauro
MSMaria Strocchia
Maria Strocchia
KFKatrin Fischer
Katrin Fischer
OWOliver Werz
Oliver Werz
GBGiuseppe Bifulco
Giuseppe Bifulco

26 January 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
STStefania Terracciano
Stefania Terracciano
ARAlessandra Russo
Alessandra Russo
MCMaria Chini
Maria Chini
MVMaria C. Vaccaro
Maria C. Vaccaro
MPMarianna Potenza
Marianna Potenza
Ines BrunoInes Bruno
Ines Bruno
Heat shock protein 90 (Hsp90) is an ATP dependent molecular chaperone deeply involved in the complex network of cellular signaling governing some key functions, such as cell proliferation and survival, invasion and angiogenesis. Over the past years the N-terminal protein domain has been fully investigated as attractive strategy against cancer, but despite the many efforts lavished in the field, none of the N-terminal binders (termed “classical inhibitors”), currently in clinical trials, have yet successfully reached the market, because of the detrimental heat shock response (HSR) that showed to induce; thus, recently, the selective inhibition of Hsp90 C-terminal domain has powerfully emerged as a more promising alternative strategy for anti-cancer therapy, not eliciting this cell rescue cascade. However, the structural complexity of the target protein and, mostly, the lack of a co-crystal structure of C-terminal domain-ligand, essential to drive the identification of new hits, represent the largest hurdles in the development of new selective C-terminal inhibitors. Continuing our investigations on the identification of new anticancer drug candidates, by using an orthogonal screening approach, here we describe two new potent C-terminal inhibitors able to induce cancer cell death and a considerable down-regulation of Hsp90 client oncoproteins, without triggering the undesired heat shock response.

12 October 2009 in European Journal of Pharmacology
Verified
Journal Article
Closed access
MGMaría Dolores Guerrero
María Dolores Guerrero
MAMaurizio Aquino
Maurizio Aquino
Ines BrunoInes Bruno
Ines Bruno
Raffaele RiccioRaffaele Riccio
Raffaele Riccio
MTM. Carmen Terencio
M. Carmen Terencio
MPMiguel Payá
Miguel Payá